Main Conference Day 3Thursday, 12 June 2025 - BST (British Summer Time, GMT+1)

This presentation highlights the development of ARGX-117, a recycling anti-C2 antibody designed to inhibit complement activation. We trace its journey from laboratory innovation to phase 2 proof-of-concept studies, showcasing its potential as a therapeutic strategy for multifocal motor neuropathy patients.

To date, over 150 drugs have been approved by the FDA for treating or preventing autoimmune and inflammatory diseases such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Despite this comprehensive arsenal of therapies, there remains a significant unmet medical need for many patient groups. Elasmogen has designed a first-in-class soloMER drug conjugate tailor-made for autoimmune and inflammatory diseases. This innovative treatment utilizes a super-potent, novel-acting multivalent anti-TNFα soloMER to site-deliver an anti-inflammatory JAK inhibitor payload, Tofacitinib.

Immunocore has developed ImmTAAI, a new class of bispecific protein therapeutic designed to deliver targeted immunomodulation to treat autoimmune diseases. The effector domain comprises an agonistic anti-PD-1 VHH, which is biologically active only when target-bound and does not compete with natural ligand (PD-L1/L2), providing a wide therapeutic index. Using this targeted approach we have developed a novel bispecific molecule which specifically targets pancreatic beta cells to potentially treat type 1 diabetes.

The central role of FcRn in regulating IgG persistence and transport provides opportunities for therapy. In particular, the depletion of IgG using FcRn antagonists represents a new class of therapeutics to treat antibody-mediated autoimmunity. Recent developments related to the modulation of IgG levels, including mechanistic aspects of FcRn antagonism, will be presented.

Barzolvolimab is a first-in-class anti-KIT monoclonal antibody designed to inhibit activation of and deplete mast cells (MC) through an allosteric mechanism. Barzolvolimab contains Fc-modifications resulting in decreased FcyR binding and enhanced pharmacokinetics. Here we describe its discovery through Phase 2 clinical development and highlight its use in patients with MC-driven disorders.